Loading
Amivantamab / Carcinoma, Non Small Cell Lung / Capmatinib · Phase 1/2 Trial
ClinicalTrials.gov · July 31, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1/2 combination study of amivantamab and capmatinib in MET-altered NSCLC registered on ClinicalTrials.gov (NCT05488314). The trial is currently active but not recruiting, with 57 participants enrolled; no efficacy or safety results are reported in this registry record.
Phase 1/2, Interventional, Non Randomized, Sequential, Open label, Treatment purpose. Carcinoma, Non-Small-Cell Lung; age from 18 Years. Intervention: Phase 1 (Combination Dose Selection); Phase 2 (Dose Expansion). n = 57. 78 sites across 13 countries.
This is a Phase 1/2 combination study of amivantamab and capmatinib in MET-altered NSCLC registered on ClinicalTrials.gov (NCT05488314). The trial is currently active but not recruiting, with 57 participants enrolled; no efficacy or safety results are reported in this registry record.
No efficacy, safety, or interim results reported in this registry record.
Clinicians and researchers should note this trial is actively enrolling or recently closed to recruitment; efficacy and safety data are not yet available in this registry record and must be obtained from published results or the sponsor.
This is an active clinical trial registry record with no posted results; it describes the planned Phase 1/2 study design and endpoints only.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and researchers should note this trial is actively enrolling or recently closed to recruitment; efficacy and safety data are not yet available in this registry record and must be obtained from published results or the sponsor.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05488314). This is a study registration, not published results. Lead sponsor: Janssen Research & Development, LLC. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 57 participants (ACTUAL). Conditions: Carcinoma, Non-Small-Cell Lung. Interventions: DRUG: Capmatinib; DRUG: Amivantamab. Primary outcome measures: Phase 1: Number of Participants with Adverse events (AEs) by Severity , Up to 2 years 1 month; Phase 1: Number of Participants with Dose Limiting Toxicities (DLTs) , Cycle 1 (Day 1 through Day 28); Phase 2: Objective Response Rate , Up to 2 years 1 month. Brief summary: The purpose of this study is to identify the recommended Phase 2 combination dose (RP2CD\[s\]) of the amivantamab and capmatinib combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection), and to evaluate the antitumor effect of the amivantamab and capmatinib combination therapy in mesenchymal-epithelial transition (MET) exon 14 skipping mutation and MET amplified NSCLC, when administered at the selected RP2CD(s) in Phase 2 (expansion).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.